AG真人官方

On 25 July 2025 Chemomab Therapeutics (CMMB) entered a Sales Agreement with LifeSci Capital enabling an 鈥渁t-the-market鈥� (ATM) issuance of American Depositary Shares (ADSs) valued at up to $7.26 million. Each ADS equals 20 ordinary shares and the offering is covered by the Company鈥檚 Form F-3 shelf registration (File No. 333-275002).

LifeSci, acting as agent, may sell ADSs on Nasdaq or through other permitted methods, in line with Chemomab鈥檚 price, timing or size parameters. Chemomab will pay a 3 % cash commission on gross proceeds and has granted customary indemnification. Neither party is obligated to consummate any sales, and the agreement may be terminated according to its terms.

The facility provides flexible, incremental access to capital but any shares issued would increase the float and may dilute existing holders. No assurance is given regarding the timing, pricing or total amount ultimately sold.

• Sales Agreement filed as Exhibit 10.1
• Legal opinion (Exhibit 5.1) and related consent (Exhibit 23.1) included

Item 5.02 鈥� Executive transition

Apple Inc. filed an 8-K announcing the Board鈥檚 appointment of Sabih Khan, 58, as Chief Operating Officer effective 25 July 2025. Khan succeeds Jeff Williams under a previously disclosed transition plan. He has served Apple since August 1995, most recently as Senior Vice President, Operations, and earlier as Vice President, Product Operations.

Khan entered into Apple鈥檚 standard executive indemnification agreement. The company stated no family relationships or related-party transactions requiring additional disclosure under Regulation S-K. The filing contains no financial data, strategic updates, or other material events.

Amaze Holdings, Inc. (NYSE American: AMZE) filed an Item 3.02 Form 8-K reporting a private placement completed between 7 July and 23 July 2025.

• Securities sold: 444,040 common shares
• Cash received: US $2,601,011 (鈮� $5.86 per share)
• Commitment shares: 2,468 additional shares issued to the investor
• Purchaser: C/M Capital Master Fund, LP
• Documentation: Transaction governed by the Securities Purchase Agreement dated 6 May 2025, previously disclosed on 7 May 2025
• Registration status: Shares issued under the Section 4(a)(2)/Rule 506(b) private-offering exemption; not registered with the SEC

The filing provides no updated financials or guidance. Proceeds strengthen liquidity, but the issuance adds to share count and may dilute existing holders. No other material events were disclosed.

Valvoline Inc. (VVV) Form 4 filing: On 07/24/2025 President & CEO Lori Ann Flees acquired 50 Deferred Stock Units (DSUs) at an implied $35.45 through the company鈥檚 2016 Deferred Compensation Plan. The transaction reflects a routine salary-deferral, not an open-market buy. After the credit, Flees directly owns 9,928 DSUs. No non-derivative share activity was reported, and no changes were disclosed to her existing common-stock position.

Absci Corporation (NASDAQ: ABSI) is issuing 16.67 million new common shares at $3.00 each via a Rule 424(b)(5) prospectus supplement, generating gross proceeds of $50.0 million. After deducting $3.0 million in underwriting fees (6%) and roughly $0.35 million in expenses, estimated net proceeds total $46.7 million. Underwriters鈥擬organ Stanley, J.P. Morgan, Jefferies and TD Cowen鈥攈old a 30-day option for an additional 2.50 million shares that could lift net proceeds to about $53.7 million.

The offering will expand outstanding shares from 127.5 million (31 Mar 25) to 144.2 million (or 146.7 million if the option is exercised), an immediate increase of roughly 13% in share count. As-adjusted tangible book value per share rises from $1.21 to $1.40, leaving new investors with $1.60 per-share dilution versus the $3.00 purchase price. The deal is priced at an 8% discount to the 23 Jul 25 closing price of $3.52.

Management intends to deploy the cash to advance internal antibody programs (ABS-101, ABS-201), enhance its AI-driven Integrated Drug Creation鈩� platform, and for general corporate purposes, with flexibility to pursue complementary acquisitions. Preliminary, unaudited liquidity was $117.5 million in cash and investments as of 30 Jun 25; the raise meaningfully extends runway toward key clinical milestones expected in 2026. Absci remains a 鈥渟maller reporting company鈥� and flags typical biotechnology and capital-markets risks, including potential share-price pressure from the enlarged float.

Haemonetics Corp. (HAE) 鈥� Form 4 Insider Transaction

On 07/24/2025 director Diane M. Bryant received 2,693 restricted stock units (RSUs) under the company鈥檚 Amended & Restated 2019 LTIP. The award is coded 鈥淎鈥� (acquisition) and will vest 100 % on the first anniversary of the grant date. Each RSU converts into one common share upon vesting. Following the grant, Bryant鈥檚 total beneficial ownership increased to 7,126 directly held shares. No derivative securities were reported.

The filing represents routine board compensation; no purchase or sale of freely-trading shares occurred, and cash was not exchanged. Dilution impact is immaterial relative to Haemonetics鈥� 50 + million shares outstanding, but the grant reinforces director-shareholder alignment.

Form 144 filed for Arista Networks (ANET) indicates a proposed sale of 162,274 common shares through J.P. Morgan Securities on 07/25/2025. The shares represent a small fraction of the 1,255,921,431 shares outstanding disclosed in the notice and have an aggregate market value of $18.66 million.

The filing also lists extensive selling activity during the prior three months by related parties, largely family trusts and individual holder Jayshree Ullal. Combined, these parties disposed of roughly 961,710 shares of ANET common stock between 06/26/2025 and 06/30/2025, generating gross proceeds that individually ranged from about $20 thousand to $54.2 million per transaction.

Rule 144 filings signal intent rather than a completed trade, yet they often precede actual insider sales. Investors may watch for execution of the planned July sale and evaluate the pattern of recent dispositions when assessing insider sentiment.

On 14 Jul 2025, HA Sustainable Infrastructure Capital, Inc. (HASI) filed an 8-K announcing the appointment of Nitya Gopalakrishnan, 53, as Executive Vice President & Chief Operating Officer.

Gopalakrishnan joins from BlackRock, where she most recently served as Managing Director & Head of Investment Infrastructure, SMA Solutions, following 25 years in senior platform, engineering and COO roles. The filing states there are no related-party relationships or transactions requiring disclosure.

The offer letter sets a $400 k base salary, target annual cash bonus equal to 125 % of salary, and a 20,000-share restricted-stock sign-on grant vesting over three years. She is also eligible for annual LTIP awards (~100 % of salary) and up to $100 k relocation reimbursement.

If terminated without cause, severance includes 12-months salary, an average prior-bonus payout, one year of health benefits, and full acceleration of all unvested equity.

No other material events, financial results, or transactions were disclosed.

Haemonetics Corporation Form 144 Notice details a proposed sale of 18,630 shares of common stock with an aggregate market value of $1,396,132.20 through Fidelity Brokerage Services on the NYSE, planned for June 26, 2025.

The shares were acquired through multiple restricted stock vestings between 2020-2025:

• 2020-2022: 469 shares total from two vestings
• 2023: 4,455 shares from three vestings
• 2025: 13,706 shares from four recent vestings

The filing also discloses a previous sale by Josep L. Llorens of 1,547 shares on May 19, 2025, generating proceeds of $107,319.26. All shares were acquired as compensation through restricted stock vestings, representing approximately 0.04% of the total 48,036,996 shares outstanding.